Boston Scientific
MassDevice.com +3 | The top 3 med-tech stories for June 11, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
BSX’s Mahoney details outlook on up-and-coming businesses, including renal denervation and ICDs
Boston Scientific’s (NYSE:BSX) got a busy road ahead, with regulatory approvals and market launches in the works for products in some of its hottest business divisions.
Did a last-minute visit from med-tech CEOs change Rep. Tsongas’ mind on device tax vote?
It would be a stretch to call it an offer she couldn’t refuse, but in the end what choice did Rep. Niki Tsongas (D-Mass.) have but to consider the pleas of the men in her Capitol Hill office last Thursday?
Tsongas represents a stretch of Massachusetts that runs from the edge of Natick to the tip of New Hampshire and includes the lion’s share of the I-495 beltway, where you can’t throw a trocar without hitting a company that either makes a medical device or services a medical device company.
Boston Scientific seals the $1.35B deal for Cameron Health
Boston Scientific (NYSE:BSX) and Cameron Health sealed the deal on a merger worth up to $1.35 billion.
Med-tech trends: Medtronic, Johnson & Johnson, Covidien, St. Jude, Boston Scientific the most talked about device makers in May
Boston Scientific lands FDA win for new stent lengths | Regulatory Roundup
Boston Scientific’s long-lasting CRM devices land new FDA labeling
Boston Scientific (NYSE:BSX) today announced that the FDA approved revised labeling for a handful of its cardiac rhythm management devices to reflect that some may last as long as 10 years before requiring replacement.
Boston Scientific touts new FDA wins for CRE dilator | Regulatory Roundup
Novation: Heart implant batteries need a boost
Device makers need to up the ante on heart implant battery life, according to group purchasing organization Novation, which controlled more than $40 billion in medical supply contracts in 2011.
Heart therapy devices with more enduring battery power mean fewer replacement surgeries for patients, which in turn means cost-savings across the board, according to the GPO, whose purchasing scale includes 47% of all surgeries in the U.S.
MassDevice.com +7 | The top 7 med-tech stories for the week of May 14, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.